IMRA America Inc. and MagArray Inc. will collaborate to develop MagArray’s novel magneto-nanoparticle immunoassay technology, which is based on research from Stanford University. The companies will jointly develop highly sensitive immunoassay sensor systems. If the work progresses as planned, IMRA will support MagArray’s development with funding of up to $10 million over the next 3½ years. IMRA also will provide scientific and technical support, including system development and nanomaterial technologies. "We see great potential for MagArray’s innovative technology to make a major impact in the diagnostics industry and to eventually play a leading role in the way that cancer and other serious diseases are diagnosed and treated,” said IMRA President Takashi Omitsu. “We have been leaders in ultrafast fiber laser research, but now we are expanding into application research, especially laser-made nanoparticles as well. I believe that our collaboration with MagArray will accelerate IMRA’s application research," he added. "MagArray’s ultimate goal is to enable better patient outcomes through better diagnostics, and IMRA is the perfect partner at the perfect time to help us accelerate our efforts toward achieving that goal. IMRA brings a wealth of life sciences and technology development expertise that complements our core technology as we build a solid foundation for our commercialization efforts," said MagArray CEO Luis Carbonell. For more information, visit: www.imra.com or www.magarray.com